Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1005 in Japanese Participants With Moderate Stage Parkinson's Disease
NCT07566429Phase 2Not yet recruiting
- Sponsor
- Bayer
- Start
- Jan 2027
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ametefgene parvec in Parkinson's disease (PD), sponsored by Bayer. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07566429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566429.